Vinorelbine tartrate-induced pulmonary edema confirmed on rechallenge.
A 67-year-old woman with metastatic breast cancer experienced sudden and profound pulmonary edema within 45 minutes after completion of intravenous administration of vinorelbine tartrate on two occasions. Both times the drug was discontinued and the patient was treated aggressively with oxygen, intravenous furosemide, and a vasodilator. The patient suffered no lasting medical complications due to the reaction. Until clear documentation and the mechanism for occurrence of this reaction are known, patients receiving vinorelbine should be monitored closely, particularly in the first few hours after intravenous administration.
Cattan
C E
CE
Miller Drug Pharmacy, Bangor, Maine, USA.
Oberg
K C
KC
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D010100:Oxygen / Q000627:therapeutic use; D011654:Pulmonary Edema / Q000139:chemically induced* / Q000188:drug therapy; D014665:Vasodilator Agents / Q000627:therapeutic use; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077235:Vinorelbine
D000972:Antineoplastic Agents, Phytogenic; D004232:Diuretics; D014665:Vasodilator Agents; D014747:Vinblastine; D005665:Furosemide; D000077235:Vinorelbine; D010100:Oxygen